INTERPACE BIOSCIENCES, INC. (IDXG) Interpace Biosciences, Inc. is a U.S.-based company specializing in advanced molecular diagnostic tests, bioinformatics, and pathology services, primarily focused on assessing cancer risk. Among its key offerings is PancraGEN, a comprehensive genomic test for pancreatic cysts and solid lesions within the pancreaticobiliary system. This test, powered by the proprietary PathFinderTG platform, assists medical professionals in more accurately determining the risk of pancreaticobiliary cancers. It also offers PanDNA, a molecular-only variant of PancraGEN, which delivers insights into a select number of diagnostic markers. For thyroid health, the company provides ThyGeNEXT, an oncogenic mutation panel designed to identify malignant thyroid nodules. Additionally, ThyraMIR evaluates thyroid nodules for malignancy risk through the application of its proprietary microRNA gene-expression assay. Furthermore, RespriDx is a genomic diagnostic tool that aids clinicians in distinguishing between metastatic and recurrent lung cancer. Interpace Biosciences further supports the pharmaceutical and biotechnology sectors with services including pharmacogenomics testing, genotyping, biorepository solutions, and various custom scientific offerings. Its clientele primarily consists of physicians, hospitals, and clinics. Previously operating as Interpace Diagnostics Group, Inc., the company adopted its current name, Interpace Biosciences, Inc., in November 2019. Founded in 1986, its corporate headquarters are located in Parsippany, New Jersey.
Sector: Surgical & Medical Instruments & Apparatus
Industry: Medical - Diagnostics & Research
Interpace Biosciences, Inc. OTC:IDXG Healthcare · Medical - Diagnostics & Research
All Press Release SEC Filings News
Press Release ⚠ 2
Interpace Biosciences Announces Preliminary Unaudited Third Quarter 2026 Revenue
Interpace Biosciences pre-announced preliminary unaudited Q3 2026 revenue of $10.1-$10.4 million, up 15-18% year-over-year.
That also represents 11-14% sequential growth from Q2 2026 revenue of $9.1 million, indicating accelerating demand for its thyroid molecular diagnostics.
The release doubles as a free writing prospectus referencing an SEC registration statement, suggesting the strong revenue print accompanies a pending securities offering.
• 12d ago AI analysis › SEC Filing ● Major ⚠ 6
IDXG: S-1/A · offering registration
Interpace Biosciences filed an amended S-1 for a firm-commitment offering of 3.1 million shares at an estimated $6.00-$7.00 per share, with estimated net proceeds of about $17.9 million (up to $20.8 million with the full 465,000-share over-allotment), underwritten solely by Lake Street Capital Markets.
SEC S-1/A • 26d ago AI analysis › News
Interpace Biosciences (OTCMKTS:IDXG) Shares Up 351.4% – Time to Buy?
defenseworld.net • 29d ago SEC Filing ● Major ⚠ 7
IDXG: S-1 · offering registration
Interpace Biosciences filed an S-1 for a $20 million firm-commitment underwritten follow-on offering, with Lake Street Capital Markets as sole bookrunner and a $3 million over-allotment option. Estimated net proceeds are $17.8 million, earmarked for working capital, capital expenditures and development of new pancreatic cyst and Barrett's Esophagus tests.
The offering is contingent on Nasdaq approval; the company currently trades on the OTCID at $6.47 (September 22, 2026) after a 1-for-5 reverse split effective August 27, 2026 to meet Nasdaq's minimum bid price.
Dilution is severe: at the assumed $6.47 price, new investors face immediate dilution of $2.01 per share, and shares outstanding rise from ~5.9 million toward ~9 million post-offering. Two private equity funds (Ampersand 46.97%, 1315 Capital 31.87%) hold ~79% pre-offering.
The thyroid business (ThyGeNEXT + ThyraMIRv2) generated $34.8M pro forma revenue and $4.4M adjusted EBITDA in 2025, growing at a ~19.7% CAGR since 2022 after PancraGEN was discontinued following CMS reimbursement loss in April 2025.
SEC S-1 • 1mo ago AI analysis › Press Release ⚠ 2
Interpace Biosciences Announces Reverse Stock Split to Support Proposed Nasdaq Uplisting
Interpace Biosciences will effect a 1-for-5 reverse stock split effective August 27, 2026, reducing outstanding shares from approximately 27.7 million to 5.5 million.
The split is primarily intended to bring the company into compliance with the minimum bid price requirement for listing on the Nasdaq Capital Market, although listing is not guaranteed.
The OTC ticker symbol will temporarily change to IDXGD for 20 trading days while the company seeks to meet the additional $15 million market value requirement.
• 2mo ago AI analysis › SEC Filing ⚠ 2
IDXG: 8-K/A · leadership change
Interpace Biosciences filed this Form 8-K/A (Amendment No. 1) to disclose that stockholders approved the adoption of the 2026 Equity Incentive Plan and the 2026 Employee Stock Purchase Plan at the annual meeting held on August 20, 2026.
The 2026 plans replace the 2019 Equity Incentive Plan and the 2019 Employee Stock Purchase Plan, and no further equity awards will be granted or ESPP purchases allowed under the 2019 plans.
The amendment adds only this Item 5.02 compensatory-arrangement disclosure plus the plan forms as exhibits (Exhibits 10.1 and 10.2); material plan terms were previously described in the definitive proxy statement filed July 7, 2026. The report was signed by President and CEO Thomas W. Burnell on August 26, 2026.
SEC 8-K/A • 2mo ago SEC Filing ● Major ⚠ 3
IDXG: 8-K · reverse split
At its 2026 annual meeting held August 20, 2026, Interpace Biosciences stockholders approved all seven proposals, including granting the Board discretionary authority to effect a reverse stock split of common stock at a ratio anywhere from one-for-two up to one-for-ten, with the exact ratio to be set by the Board within one year of the approval.
Stockholders also approved an amended and restated certificate of incorporation (about 25.0 million votes for versus 0.25 million against), the 2026 Equity Incentive Plan, and the 2026 Employee Stock Purchase Plan, each passing by wide margins.
All five director nominees (Aggarwal, Burnell, Keegan, Rocca, Sullivan) were elected, the advisory say-on-pay vote passed, and EisnerAmper was ratified as independent auditor for fiscal 2026. The headline item is the reverse split authorization: with the cover page showing no securities registered on a national exchange, the split suggests an effort to shore up the OTC quote or potentially prepare for a re-listing, and the final ratio decision now rests with the Board.
SEC 8-K • 2mo ago News
Critical Contrast: Interpace Biosciences (OTCMKTS:IDXG) versus Ethema Health (OTCMKTS:GRST)
defenseworld.net • 2mo ago SEC Filing ⚠ 6
IDXG: 10-Q · periodic report
Interpace Biosciences swung back to quarterly profitability, posting Q2 2026 net income of $158 thousand ($0.01 diluted EPS) versus a $640 thousand loss ($-0.14) a year earlier, as net revenue slipped 1% to $9.1 million and gross margin improved to 61.9%.
First-half 2026 revenue fell 12% to $18.2 million from $20.7 million, driven by CMS's April 2025 decision to cease reimbursement of the PancraGEN pancreatic test; the company now concentrates on its ThyGeNEXT and ThyraMIRv2 thyroid tests, with LabCorp as its largest customer, and is developing a new pancreatic test that needs a CMS coverage determination of unknown timing.
The balance sheet is debt-free but thin: cash was $2.7 million at both June 30 and July 31, 2026, operating cash flow was $0.4 million for the half, and management expects liquidity to be sufficient for the next twelve months while exploring equity and debt financing and strategic alternatives.
A January 2026 conversion of all 47,000 Series C preferred shares at a $2.02 price added 23.3 million common shares, leaving backers Ampersand (~50%) and 1315 Capital (~34%) in control of 84% of the stock, which now trades on OTCID after the 2021 Nasdaq delisting and August 2025 OTCQX removal; a Nasdaq uplisting is being pursued with no assurance of success.
SEC 10-Q • 2mo ago AI analysis › Press Release ⚠ 2
Interpace Biosciences Announces Second Quarter 2026 Financial and Business Results
Interpace Biosciences reported Q2 2026 revenue of $9.1 million, a 1% decrease from the prior year due to the discontinuation of the PancraGEN business.
On a Pro Forma thyroid-only basis, revenue increased 9% year-over-year, driving income from continuing operations of $0.3 million and gross margin expansion to 62%.
Adjusted EBITDA improved to $0.7 million, and the company announced the appointment of a new Chief Scientific Officer to advance its molecular diagnostics platform.
• 2mo ago AI analysis › SEC Filing ⚠ 4
IDXG: DEF 14A · proxy statement
Interpace Biosciences has filed a definitive proxy statement for its 2026 Annual Meeting of Stockholders, soliciting approval for a reverse stock split within a range of 1-for-2 to 1-for-10. The principal stated purpose of the split is to increase the share price to meet initial listing requirements for uplisting to the Nasdaq Capital Market from the OTC market. Additionally, the company is seeking approval to amend its Certificate of Incorporation to double the number of authorized common shares to 200 million and to declassify the board of directors.
The proxy statement outlines the ratification of EisnerAmper as the independent auditor and requests approval for the company's new 2026 Equity Incentive Plan and 2026 Employee Stock Purchase Plan. The 2026 plan authorizes 4.4 million shares for new awards to incentivize employees, replacing the 2019 plan, and includes specific prospective grants for executive officers and non-employee directors.
Stockholders are asked to elect five nominees—Vijay Aggarwal, Thomas Burnell, Joseph Keegan, Fortunato Ron Rocca, and Stephen J. Sullivan—to serve as directors. The board also recommends a non-binding advisory vote to approve executive compensation, which is being conducted on a triennial basis.
SEC DEF 14A • 3mo ago SEC Filing
IDXG: PREM14A · proxy statement
Interpace Biosciences, Inc. has filed a preliminary proxy statement (Schedule 14A) with the Securities and Exchange Commission. The submission serves as a notification of the upcoming solicitation of proxies.
The provided text is limited to the cover page information and does not yet disclose the date of the shareholder meeting, specific proposals, or executive compensation details. Investors should await the definitive proxy statement or amended filings for material information regarding corporate governance and matters to be voted upon.
SEC PREM14A • 4mo ago SEC Filing ⚠ 3
IDXG: 8-K · earnings release
Interpace Biosciences reported Q1 2026 revenue of $9.0 million, representing a 12% year-over-year increase in thyroid-specific revenue and a 14% increase on a pro-forma basis after excluding the discontinued PancraGEN business.
The company delivered $0.8 million in income from continuing operations and $1.6 million in Adjusted EBITDA, with gross margin expanding to 65% and operating margin improving to 12% on a pro-forma basis, reflecting operational efficiency gains.
Management reaffirmed its 2026 guidance of approximately 16% year-over-year thyroid revenue growth, citing a debt-free balance sheet, improved turnaround times, and continued adoption of its ThyGeNEXT and ThyraMIRv2 diagnostic platforms.
SEC 8-K • 5mo ago AI analysis › SEC Filing ⚠ 3
IDXG: 10-Q · periodic report
Interpace Biosciences, Inc. reported a 22% decrease in revenue to $9.0 million for the quarter ended March 31, 2026, compared to $11.5 million in the same period of 2025. This decline is primarily attributed to the loss of reimbursement for the PancraGEN® test, which was discontinued in May 2025.
The company's net income for the quarter was $0.721 million, a significant decrease from $1.647 million in the same period of 2025. The decrease in net income is largely due to the reduced revenue and gross profit, which fell from $7.4 million to $5.9 million.
As of March 31, 2026, Interpace had cash and cash equivalents of $2.6 million, and total current assets of $10.0 million. The company's current liabilities were $4.0 million, and it had a total of $27.7 million in shares of Common Stock outstanding.
The company continues to explore various strategic alternatives, including equity and debt financings, to provide additional liquidity. However, the delisting of its Common Stock from Nasdaq in February 2021 has adversely impacted its ability to raise capital on favorable terms.
SEC 10-Q • 5mo ago AI analysis › Press Release ● Major
Interpace Biosciences Announces First Quarter 2026 Financial and Business Results
globenewswire.com • 5mo ago News
Head to Head Contrast: Retractable Technologies (NYSE:RVP) & Interpace Biosciences (OTCMKTS:IDXG)
defenseworld.net • 6mo ago News
Head to Head Analysis: Dynatronics (NASDAQ:DYNT) versus Interpace Biosciences (OTCMKTS:IDXG)
defenseworld.net • 6mo ago News
Interpace Biosciences (OTCMKTS:IDXG) Stock Crosses Above 200-Day Moving Average – Here’s What Happened
defenseworld.net • 6mo ago Recent SEC filings with analysis 
